amiodarone has been researched along with Nervous System Diseases in 17 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Nervous System Diseases: Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We compared the efficacy and safety of amiodarone and dronedarone in patients with persistent atrial fibrillation (AF)." | 9.14 | A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. ( Davy, JM; De Ferrari, GM; Le Heuzey, JY; Radzik, D; Santini, M; Zhu, J, 2010) |
| "Gestational exposure to amiodarone may be complicated by perinatal hypothyroidism or hyperthyroidism and possibly neurologic abnormalities, intrauterine growth retardation or fetal bradycardia." | 7.69 | Pregnancy outcome after gestational exposure to amiodarone in Canada. ( Allen, LC; Boulton, BC; Downar, E; Koren, G; Magee, LA; Sermer, M, 1995) |
| "The effect of low-dose amiodarone was prospectively evaluated in 110 patients with potentially lethal ventricular arrhythmias and structural heart disease." | 7.67 | Long-term efficacy, safety and survival of patients with potentially lethal ventricular arrhythmias treated with low-dose amiodarone. ( Aragon, E; Blevins, RD; Faitel, K; Frumin, H; Jarandilla, R; Kerin, NZ; Luarca, R; Marinescu, G; Rubenfire, M, 1988) |
| "AHs/MHs can be associated with hypoacusis, psychiatric or neurological diseases, intoxication and adverse reactions of different medications (e." | 5.62 | Amiodarone-induced musical hallucinations. ( Elikowski, W; Fertała, N; Małek-Elikowska, M; Zawodna-Marszałek, M, 2021) |
| "We compared the efficacy and safety of amiodarone and dronedarone in patients with persistent atrial fibrillation (AF)." | 5.14 | A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. ( Davy, JM; De Ferrari, GM; Le Heuzey, JY; Radzik, D; Santini, M; Zhu, J, 2010) |
| "Gestational exposure to amiodarone may be complicated by perinatal hypothyroidism or hyperthyroidism and possibly neurologic abnormalities, intrauterine growth retardation or fetal bradycardia." | 3.69 | Pregnancy outcome after gestational exposure to amiodarone in Canada. ( Allen, LC; Boulton, BC; Downar, E; Koren, G; Magee, LA; Sermer, M, 1995) |
| "One hundred two patients with recurrent, drug-refractory tachyarrhythmias were treated with amiodarone for nine +/- eight months (mean +/- SD) (range, one to 50 months)." | 3.67 | Unusual neurotoxicity associated with amiodarone therapy. ( Iyer, V; Meckler, RJ; Palakurthy, PR, 1987) |
| "The effect of low-dose amiodarone was prospectively evaluated in 110 patients with potentially lethal ventricular arrhythmias and structural heart disease." | 3.67 | Long-term efficacy, safety and survival of patients with potentially lethal ventricular arrhythmias treated with low-dose amiodarone. ( Aragon, E; Blevins, RD; Faitel, K; Frumin, H; Jarandilla, R; Kerin, NZ; Luarca, R; Marinescu, G; Rubenfire, M, 1988) |
| "Rats were treated with amiodarone (20 mg/kg/day) up to 6 weeks and the neurotoxicity was assessed by determining changes in motor coordination, pain-threshold and rectal temperature every week during treatment." | 3.67 | Neurotoxicity in rats following subchronic amiodarone treatment. ( Fernando, JC; Ho, IK; Mehendale, HM; Rao, KS, 1986) |
| "Amiodarone, a drug used to treat refractory cardiac arrhythmias, produced a peripheral neuropathy in 5 of 50 cases (10%)." | 3.66 | Amiodarone neuropathy. ( Martinez-Arizala, A; McCarty, GE; Nichols, BR; Rakita, L; Sobol, SM, 1983) |
| "AHs/MHs can be associated with hypoacusis, psychiatric or neurological diseases, intoxication and adverse reactions of different medications (e." | 1.62 | Amiodarone-induced musical hallucinations. ( Elikowski, W; Fertała, N; Małek-Elikowska, M; Zawodna-Marszałek, M, 2021) |
| "Five patients developed neurological adverse effects as they were treated with amiodarone for 2 to 18 months." | 1.28 | [Neurological toxicity of amiodarone. 5 case reports]. ( Arnaud, A; Gil, R; Marechaud, R; Neau, JP; Rivasseau-Jonveaux, T, 1992) |
| "Paraesthesiae, ataxia, vertigo and tremor were the most common (7-9%)." | 1.28 | Survey of neurological problems with amiodarone in the New Zealand Intensive Medicines Monitoring Programme. ( Coulter, DM; Edwards, IR; Savage, RL, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (52.94) | 18.7374 |
| 1990's | 5 (29.41) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (11.76) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Elikowski, W | 1 |
| Małek-Elikowska, M | 1 |
| Fertała, N | 1 |
| Zawodna-Marszałek, M | 1 |
| Su, M | 1 |
| Seki, D | 1 |
| Moheet, AM | 1 |
| Le Heuzey, JY | 1 |
| De Ferrari, GM | 1 |
| Radzik, D | 1 |
| Santini, M | 1 |
| Zhu, J | 1 |
| Davy, JM | 1 |
| Martinez-Arizala, A | 1 |
| Sobol, SM | 1 |
| McCarty, GE | 1 |
| Nichols, BR | 1 |
| Rakita, L | 1 |
| Charness, ME | 1 |
| Morady, F | 1 |
| Scheinman, MM | 1 |
| Magee, LA | 1 |
| Downar, E | 1 |
| Sermer, M | 1 |
| Boulton, BC | 1 |
| Allen, LC | 1 |
| Koren, G | 1 |
| Besser, R | 1 |
| Treese, N | 1 |
| Bohl, J | 1 |
| Goebel, HH | 1 |
| Shukla, R | 1 |
| Jowett, NI | 1 |
| Thompson, DR | 1 |
| Pohl, JE | 1 |
| Bady, B | 1 |
| Bourrat, C | 1 |
| Trillet, M | 1 |
| Girard, PF | 1 |
| Carrier, H | 1 |
| Kaeser, HE | 1 |
| Ulrich, J | 1 |
| Wüthrich, R | 1 |
| Arnaud, A | 1 |
| Neau, JP | 1 |
| Rivasseau-Jonveaux, T | 1 |
| Marechaud, R | 1 |
| Gil, R | 1 |
| Coulter, DM | 1 |
| Edwards, IR | 1 |
| Savage, RL | 1 |
| Wemeau, J | 1 |
| Montagne, B | 1 |
| Gras, E | 1 |
| Costa-Jussà, FR | 1 |
| Jacobs, JM | 1 |
| Palakurthy, PR | 1 |
| Iyer, V | 1 |
| Meckler, RJ | 1 |
| Kerin, NZ | 1 |
| Rubenfire, M | 1 |
| Blevins, RD | 1 |
| Frumin, H | 1 |
| Faitel, K | 1 |
| Jarandilla, R | 1 |
| Aragon, E | 1 |
| Marinescu, G | 1 |
| Luarca, R | 1 |
| Rao, KS | 1 |
| Fernando, JC | 1 |
| Ho, IK | 1 |
| Mehendale, HM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| First-line Cryoablation for Early Treatment of Persistent Atrial Fibrillation - a Randomized Study Comparing Early Trigger Isolation Using the Cryoballoon Versus Antiarrhythmic Medication[NCT05939076] | Phase 3 | 220 participants (Anticipated) | Interventional | 2023-08-21 | Not yet recruiting | ||
| Randomized Double Blind Trial to Evaluate the Efficacy and Safety of Dronedarone (400mg BID) Versus Amiodarone (600mg Daily for 28 Days, Then 200mg Daily Thereafter) for at Least 6 Months for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrill[NCT00489736] | Phase 3 | 504 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Pragmatic Randomized Clinical Trial of Early Dronedarone Versus Usual Care to Change and Improve Outcomes in Persons With First-Detected Atrial Fibrillation[NCT05130268] | Phase 4 | 3,000 participants (Anticipated) | Interventional | 2021-10-29 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The considered event is the occurrence of the MSE defined as thyroid, hepatic, pulmonary, neurological, skin, eye, or gastrointestinal specific treatment emergent events or premature study drug discontinuation following any adverse event (AE), whichever comes first. The analysis is performed on the time from first study drug intake to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period." (NCT00489736)
Timeframe: minimum study duration is 6 months (+10 days); maximum is 15 months
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 83 |
| Amiodarone 600mg/200mg od | 107 |
"The considered event is the occurrence of the MSE excluding gastrointestinal specific treatment emergent events defined as diarrhoea, nausea, vomiting. The analysis is performed on the time from first study drug intake to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period." (NCT00489736)
Timeframe: minimum study duration is 6 months (+10 days); maximum is 15 months
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 61 |
| Amiodarone 600mg/200mg od | 99 |
"The primary event is the treatment failure defined as the first recurrence of atrial fibrillation or premature study drug discontinuation for intolerance or lack of efficacy according to the investigator judgement. The primary efficacy analysis is performed on the time from first study drug intake to this primary event. The Measured Values table below presents the numbers of patients with the event at the end of the study period." (NCT00489736)
Timeframe: minimum study duration is 6 months (+10 days); maximum is 15 months
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 184 |
| Amiodarone 600mg/200mg od | 141 |
1 review available for amiodarone and Nervous System Diseases
| Article | Year |
|---|---|
[Toxic neurologic manifestations during angina pectoris treatment (perhexiline maleate and amiotadone hydrochloride)].
Topics: Amiodarone; Angina Pectoris; Benzofurans; Cerebrospinal Fluid Proteins; Electromyography; Humans; In | 1978 |
1 trial available for amiodarone and Nervous System Diseases
15 other studies available for amiodarone and Nervous System Diseases
| Article | Year |
|---|---|
Amiodarone-induced musical hallucinations.
Topics: Aged; Amiodarone; Hallucinations; Hearing Loss; Humans; Male; Music; Nervous System Diseases | 2021 |
Pharmacologic cardioversion with intravenous amiodarone is likely safe in neurocritically Ill patients.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fib | 2017 |
Amiodarone neuropathy.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Female; Humans; Male; Middle Aged; Nervous Syst | 1983 |
Frequent neurologic toxicity associated with amiodarone therapy.
Topics: Amiodarone; Ataxia; Benzofurans; Female; Humans; Male; Middle Aged; Nervous System Diseases; Tremor | 1984 |
Pregnancy outcome after gestational exposure to amiodarone in Canada.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Arrhythmias, Cardiac; Bradycardia; Canada; Cohort St | 1995 |
[Clinical, neurophysiologic and biopsy findings in neurotoxic amiodarone syndrome].
Topics: Amiodarone; Dose-Response Relationship, Drug; Evoked Potentials, Somatosensory; Follow-Up Studies; H | 1994 |
Side effects with amiodarone therapy.
Topics: Aged; Amiodarone; Drug Administration Schedule; Drug Eruptions; Female; Humans; Male; Middle Aged; N | 1994 |
Amiodarone neuropathy (author's transl).
Topics: Amiodarone; Angina Pectoris; Benzofurans; Demyelinating Diseases; Humans; Male; Middle Aged; Nervous | 1976 |
[Neurological toxicity of amiodarone. 5 case reports].
Topics: Age Factors; Aged; Aged, 80 and over; Alcoholism; Amiodarone; Diabetes Complications; Female; Humans | 1992 |
Survey of neurological problems with amiodarone in the New Zealand Intensive Medicines Monitoring Programme.
Topics: Amiodarone; Ataxia; Humans; Nervous System Diseases; New Zealand; Paresthesia; Product Surveillance, | 1990 |
[Neurologic side effects of amiodarone].
Topics: Amiodarone; Benzofurans; Humans; Male; Middle Aged; Nervous System Diseases | 1986 |
The pathology of amiodarone neurotoxicity. I. Experimental studies with reference to changes in other tissues.
Topics: Amiodarone; Animals; Benzofurans; Mice; Mice, Inbred BALB C; Nervous System Diseases; Neurotoxins; P | 1985 |
Unusual neurotoxicity associated with amiodarone therapy.
Topics: Aged; Amiodarone; Brain Diseases; Brain Stem; Female; Humans; Jaw; Male; Middle Aged; Movement Disor | 1987 |
Long-term efficacy, safety and survival of patients with potentially lethal ventricular arrhythmias treated with low-dose amiodarone.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Corneal Diseases; Female; Follow-Up Studies; Humans; Male; M | 1988 |
Neurotoxicity in rats following subchronic amiodarone treatment.
Topics: Amiodarone; Animals; Benzofurans; Body Temperature; Body Weight; Drinking Behavior; Feeding Behavior | 1986 |